Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioenvision
Bioenvision receives European approval for Evoltra
July 4th, 2006
Bioenvision, Inc., (BIVN) announced the European Commission has granted marketing authorization for Evoltra (clofarabine) for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. The licensed indication includes patients who were <21 years at the time of initial diagnosis of their leukemia. "This is a momentous day for children suffering from ALL and the doctors who treat them," said Hugh Griffith, Bioenvision's chief operating officer. "By approving Evoltra in Europe the...
Source: Pharma Law Weekly (2006-07-04)
|
